Natixis’s bluebird bio BLUE Stock Holding History

Natixis’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-9,740	Closed	-$5.46M	–	1073
2020 Q4	$5.46M	Buy	+9,740	New	+$6.17M	0.02%	498
2020 Q3	–	Sell	-4,045	Closed	-$3.2M	–	769
2020 Q2	$3.2M	Buy	+4,045	New	+$3.05M	0.02%	352

Other funds holding BLUE

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Natixis's BLUE Position: Q1 2021 in Review

Natixis sold out of bluebird bio (BLUE) in Q1 2021, closing a stake of 9,740 shares — an estimated $5.46M sold.

Natixis first reported a position in BLUE in Q2 2020 and held it in 2 quarters. The position peaked at $5.46M in Q4 2020. 229 funds tracked by Wall St. Rank hold BLUE as of Q1 2021.

Natixis reported no remaining bluebird bio position as of Q1 2021 after selling out during the quarter.
Natixis sold 9,740 bluebird bio shares in Q1 2021, an estimated $5.46M.
Natixis first reported a position in bluebird bio in Q2 2020 and held it in 2 quarters.
Natixis's bluebird bio position peaked at $5.46M in Q4 2020.
229 funds tracked by Wall St. Rank held bluebird bio as of Q1 2021.

Based on Natixis's 13F filing for Q1 2021, filed 14 May 2021.